PT
PTGX.US Protagonist Therapeutics Inc
- Market cap
- USD 8.05B
- P/E
- 26.1x
- P/B
- 7.87x
- ROE
- 47.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PTGX.US undervalued?
Graham numberThe Graham number of Protagonist Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Protagonist Therapeutics Inc fundamental analysis
No fundamental analysis for Protagonist Therapeutics Inc yet.
Protagonist Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia ve…
Full company profileProtagonist Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Protagonist Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 20.1M | 30.9M | 231K | 28.6M | 27.4M | 26.6M | 60.0M | 434M | 46.0M | 726M |
| Gross Profit | -317K | 20.1M | 30.9M | 231K | 28.6M | 27.4M | 26.6M | 60.0M | 434M | 44.8M | 724M |
| Operating Income | -32.7M | -37.9M | -42.3M | -80.5M | -64.5M | -126M | -131M | -93.7M | 253M | -158M | 498M |
| EBITDA | -32.3M | -37.5M | -41.7M | -75.2M | -61.8M | -123M | -128M | -75.6M | 282M | -128M | 526M |
| Net Income | -37.2M | -37.0M | -38.9M | -77.2M | -66.2M | -126M | -123M | -79.0M | 275M | -130M | 516M |
| EPS | -5.72 | -2.09 | -1.74 | -2.98 | -1.92 | -2.71 | -2.52 | -1.39 | 4.23 | -2.05 | 7.19 |
| Balance Sheet | |||||||||||
| Total Assets | 94.0M | 164M | 139M | 155M | 324M | 348M | 248M | 358M | 745M | 670M | 1.15B |
| Total Liabilities | 6.44M | 43.1M | 27.0M | 75.0M | 44.9M | 47.7M | 32.3M | 21.3M | 69.4M | 55.2M | 61.6M |
| Shareholders' Equity | -64.6M | -102M | -140M | 80.0M | 280M | 300M | 216M | 337M | 675M | 615M | 1.08B |
| Cash & Short-term Investments | 77.6M | 144M | 129M | 133M | 306M | 327M | 237M | 342M | 419M | 567M | 800M |
| Total Debt | - | - | - | 17.0M | 5.96M | 5.86M | 3.66M | 1.14M | 10.9M | 10.3M | 8.63M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -30.0M | 3.87M | -49.9M | -41.5M | -72.5M | -108M | -108M | -70.2M | 184M | 57.7M | 196M |
| Capital Expenditure | 379K | 666K | 486K | 967K | 471K | 1.10M | 795K | 609K | 1.36M | 1.59M | 827K |
| Free Cash Flow | -30.4M | 3.21M | -50.4M | -42.5M | -73.0M | -109M | -109M | -70.8M | 183M | 56.1M | 195M |
| Ratios | |||||||||||
| ROE | - | - | - | -96.5% | -23.7% | -41.8% | -57.2% | -23.5% | 40.8% | -21.2% | 47.5% |
| ROA | -39.6% | -22.6% | -27.9% | -49.8% | -20.4% | -36.1% | -49.8% | -22.1% | 37.0% | -19.4% | 45.0% |
| Net Profit Margin | - | -184.2% | -125.9% | -33,414.3% | -231.1% | -458.9% | -464.3% | -131.6% | 63.3% | -282.8% | 71.0% |
| Debt to Equity | - | - | - | 0.21x | 0.02x | 0.02x | 0.02x | 0.00x | 0.02x | 0.02x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Protagonist Therapeutics Inc dividends
Protagonist Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Protagonist Therapeutics Inc
- Insiders 0.70%
- Institutions 99.30%
- Public & others 0.00%
- Shares outstanding 65.3M
- Free float 53.5M
Top funds holding PTGX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 3.89M | 5.96% | -0.06% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.05M | 3.14% | +0.01% | Sep 2026 |
| iShares Russell 2000 ETF | 1.56M | 2.39% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.46M | 2.23% | -1.63% | Sep 2026 |
| Vanguard Health Care Inv | 1.24M | 1.91% | -9.91% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.09M | 1.67% | +2.67% | Oct 2026 |
| Vanguard Explorer Inv | 1.02M | 1.56% | +94.54% | Sep 2026 |
| Invesco Discovery A | 887K | 1.36% | +10.04% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 811K | 1.24% | -4.48% | Sep 2026 |
| Fidelity Small Cap Index | 674K | 1.03% | +0.14% | Aug 2026 |
| Fidelity Select Biotechnology | 608K | 0.93% | 0.00% | Aug 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 591K | 0.91% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 583K | 0.89% | -0.20% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 580K | 0.89% | -0.38% | Oct 2026 |
| Invesco S&P SmallCap Momentum ETF | 570K | 0.87% | 0.00% | Oct 2026 |
| T. Rowe Price Health Sciences | 525K | 0.80% | -1.57% | Sep 2026 |
| Janus Henderson Triton D | 479K | 0.73% | -7.37% | Sep 2026 |
| iShares Biotechnology ETF | 476K | 0.73% | -0.36% | Oct 2026 |
| American Century Small Cap Growth Inv | 456K | 0.70% | 0.00% | Sep 2026 |
| Hood River Small-Cap Growth Instl | 438K | 0.67% | -1.74% | Jun 2026 |
Top institutions holding PTGX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 10.3M | 15.79% | +5.40% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 6.35M | 9.73% | 0.00% | Jun 2026 |
| RTW INVESTMENTS, LLC | 5.06M | 7.75% | +0.04% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.63M | 5.56% | +4.25% | Jun 2026 |
| Wellington Management Company LLP | 3.42M | 5.23% | -5.08% | Jun 2026 |
| UBS Group AG | 3.40M | 5.21% | -34.35% | Jun 2026 |
| State Street Corp | 3.32M | 5.09% | +6.57% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.85M | 4.37% | +1.69% | Jun 2026 |
| Johnson & Johnson | 2.45M | 3.75% | 0.00% | Jun 2026 |
| Amvescap Plc. | 2.34M | 3.59% | +8.13% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.15M | 3.29% | +29.07% | Jun 2026 |
| Jupiter Topco LLC | 2.13M | 3.26% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.74M | 2.67% | +4.30% | Jun 2026 |
| Woodline Partners LP | 1.41M | 2.17% | 0.00% | Jun 2026 |
| Bank of America Corp | 1.32M | 2.03% | +2.24% | Jun 2026 |
| Jennison Associates LLC | 1.15M | 1.76% | +7.43% | Jun 2026 |
| Perceptive Advisors LLC | 982K | 1.50% | -20.23% | Jun 2026 |
| ADAR1 Capital Management LLC | 961K | 1.47% | -3.35% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 906K | 1.39% | -11.02% | Jun 2026 |
| Alyeska Investment Group, L.P. | 889K | 1.36% | +49.92% | Jun 2026 |
Protagonist Therapeutics Inc company profile
- Company name
- Protagonist Therapeutics Inc
- Ticker
- PTGX.US
- Exchange
- USA Stocks
- Listed since
- Aug 11, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 149
- Fiscal year end
- December
- Address
- 7707 Gateway Boulevard, Newark, CA, United States, 94560
- Phone
- 510 474 0170
- Website
- protagonist-inc.com
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics Inc management
10- Dr. Dinesh V. Patel Ph.D.CEO, President, Secretary & Director · born 1957
- Mr. Asif AliExecutive VP & CFO · born 1974
- Dr. Arturo M. Molina FACP, M.D., M.S.Chief Medical Officer · born 1959
- Mr. Venkat Thalladi Ph.D.EVP & Chief Technical Officer
- Dr. Newman Yeilding M.D.Executive VP, Chief Scientific Officer
- Mr. Matthew M. Gosling J.D.Executive VP and Chief Legal & Business Officer · born 1971
- Ms. Carena SpiveyExecutive VP & Chief Human Resources Officer
- Dr. Ashok Bhandari Ph.D.EVP & Chief Discovery Officer · born 1964
- Mr. Carter J. KingExecutive Vice President of Business Development · born 1971
- Ms. Abha BommireddiExecutive VP & Chief of Staff